Compare Natera Inc. Common Stock (NTRA) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Direxion Daily FTSE China Bull 3x Shares trades at $24.01 (market cap $600.54M). The key difference: Natera Inc. Common Stock is far larger — about 95× Direxion Daily FTSE China Bull 3x Shares's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Direxion Daily FTSE China Bull 3x Shares for 26 Days on average.
| NTRA | YINN | |
|---|---|---|
Market Cap | $57.03B | $600.54M |
Volume | 1,131,157 | 729,546 |
Sector | Health | Leveraged / Inverse |
52-Week High | $425.64 | $52.69 |
52-Week Low | $179.42 | $21.45 |
Typical Hold Time | 0 Days | 26 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
YINN trades at $25.06, up 0.36% with bearish technical signals from moving averages. The stock shows neutral momentum oscillators with RSI at 44.85. Recent news highlights China's economic policies affecting Asian markets, though YINN's specific financial metrics remain undisclosed in current data. The stock faces concentrated support/resistance around $25.
Outlook remains cautious with technical indicators suggesting bearish pressure. Investment opportunity depends on China's economic recovery and policy developments. Key risks include regulatory changes and market volatility. Analyst consensus and institutional positioning data are currently unavailable for assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
